Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.50 |
| ▸ | FEN1 | P39748 | 1/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.49 |
| ▸ | IKBKB | O14920 | 2/20 | 0.48 |
| ▸ | CHUK | O15111 | 2/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | FPR1 | P21462 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.47 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.47 |
| ▸ | TUBB | P07437 | 2/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5797256 | 0.98 | BCAT2 (0.69) | BCAT2SLC6A4SLC6A3ALOX5APFEN1 | |
| SCHEMBL5878337 | 0.90 | BCAT2 (0.87) | BCAT2SLC6A4SLC6A3ALOX5APFEN1 | |
| SCHEMBL30582476 | 0.88 | BCAT2 (0.83) | BCAT2SLC6A4SLC6A3ALOX5APFEN1 | |
| SCHEMBL27588152 | 0.85 | SLC6A3 (0.77) | BCAT2SLC6A4SLC6A3GRM2PTGS1 | |
| SCHEMBL28231510 | 0.84 | SLC6A3 (0.66) | BCAT2SLC6A4SLC6A3PTGS1PTGS2 | |
| SCHEMBL31140008 | 0.84 | BCAT2 (0.92) | BCAT2IKBKBCHUKCHEK1MAPT | |
| SCHEMBL132986 | 0.84 | BCAT2 (1.00) | BCAT2IKBKBCHUKCHEK1MAPT | |
| SCHEMBL29427545 | 0.84 | BCAT2 (1.00) | BCAT2IKBKBCHUKCHEK1MAPT | |
| SCHEMBL16149659 | 0.84 | BCAT2 (0.91) | BCAT2IKBKBCHEK1MAPTNPC1 | |
| SCHEMBL3236362 | 0.83 | BCAT2 (0.63) | BCAT2SLC6A4SLC6A3ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| EP-2097379-A1 | CARBOXAMIDE DERIVATIVES AS ION CHANNEL MODULATORS | Wyeth a Corporation of the State of Delaware (US) | 2009-09-09 | — | — | EP | claimed |
| EP-1252140-B1 | PYRROLECARBOXAMIDES AND PYRROLETHIOAMIDES AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2009-05-13 | — | — | EP | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| WO-2008073936-A1 | CARBOXAMIDE DERIVATIVES AS ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| EP-1042276-A1 | THIOUREA COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY LLC (US) | 2000-10-11 | — | — | EP | claimed |
| WO-1999032433-A1 | THIOUREA AND BENZAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1999-07-01 | — | — | WO | claimed |
| CN-110483496-A | One kind has the application of uracil-benzothiazole structure derivative, preparation method and anti-HCV medicament | XIXI HOSPITAL OF HANGZHOU | 2019-11-22 | — | — | CN | disclosed |
| CN-110072842-A | Molecules having pesticidal utility, and intermediates, compositions and methods related thereto | 美国陶氏益农公司 | 2019-07-30 | — | — | CN | disclosed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | disclosed |
| EP-3303299-A1 | IMIDAZOLE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-04-11 | — | — | EP | disclosed |
| CN-107734969-A | Molecules having pesticidal utility, and intermediates, compositions and methods related thereto | 美国陶氏益农公司 | 2018-02-23 | — | — | CN | disclosed |
| EP-2382194-A2 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | RESVERLOGIX CORP. (CA) | 2011-11-02 | — | — | EP | disclosed |
| WO-2009152824-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2009-12-23 | — | — | WO | disclosed |
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | PRLHR, PTGDR, TACR1 | BCAT2 2941/4885SLC6A4 987/4885SLC6A3 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.